Hepatitis Monthly

Published by: Kowsar

Model for Non-Invasive Diagnosis of NAFLD Incorporating Caspase 3-Cleaved Cytokeratin-18: A Clinical, Serological, and Immunohistochemical Analysis

Hatem Elalfy 1 , * , Tarek Besheer 1 , Dina Elhammady 1 , Mie A Mohamed 2 , Mona Abo-Bakr El-Hussiny 3 , Wagdi Elkashef 2 , Basem Salama El-Deek 4 and Sahar Alsayed Mohamed Alsayed 3
Authors Information
1 Endemic Medicine Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 Pathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 Clinical Pathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
4 Community Medicine Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
Article information
  • Hepatitis Monthly: April 2018, 18 (4); e60168
  • Published Online: April 28, 2018
  • Article Type: Research Article
  • Received: August 18, 2017
  • Revised: February 8, 2018
  • Accepted: February 28, 2018
  • DOI: 10.5812/hepatmon.60168

To Cite: Elalfy H, Besheer T, Elhammady D, Mohamed M A, El-Hussiny M A, et al. Model for Non-Invasive Diagnosis of NAFLD Incorporating Caspase 3-Cleaved Cytokeratin-18: A Clinical, Serological, and Immunohistochemical Analysis, Hepat Mon. 2018 ; 18(4):e60168. doi: 10.5812/hepatmon.60168.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58(6):1375-92. x. doi: 10.1016/j.pcl.2011.09.005. [PubMed: 22093857].
  • 2. Cave M, Falkner KC, Ray M, Joshi-Barve S, Brock G, Khan R, et al. Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology. 2010;51(2):474-81. doi: 10.1002/hep.23321. [PubMed: 19902480].
  • 3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23. doi: 10.1002/hep.25762. [PubMed: 22488764].
  • 4. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35(2):373-9. doi: 10.1053/jhep.2002.30692. [PubMed: 11826411].
  • 5. Herion DW, Arioglu E, Doo E, Kleiner D, Taylor SI, Liang TJ, et al. Severe insulin resistance syndromes and nonalcoholic steatohepatitis. Abstracts of a symposium presented by National Institutes of Diabetes, Digestive and Kidney Disease, National Institutes of Health and the Office of Research on Women's Health-OD, December 10-11. Bethesda, MD; 1998.
  • 6. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;9(3):299-314. doi: 10.2174/156652409787847191. [PubMed: 19355912].
  • 7. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135(1):100-10. doi: 10.1053/j.gastro.2008.03.078. [PubMed: 18503774].
  • 8. Mahmoud AA, Bakir AS, Shabana SS. Serum TGF-beta, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J Gastroenterol. 2012;18(5):327-33. doi: 10.4103/1319-3767.101132. [PubMed: 23006461].
  • 9. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072-8. doi: 10.1002/hep.23050. [PubMed: 19585618].
  • 10. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205-19. doi: 10.1016/S0092-8674(04)00046-7. [PubMed: 14744432].
  • 11. Thapaliya S, Wree A, Povero D, Inzaugarat ME, Berk M, Dixon L, et al. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig Dis Sci. 2014;59(6):1197-206. doi: 10.1007/s10620-014-3167-6. [PubMed: 24795036].
  • 12. Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One. 2013;8(12). e82092. doi: 10.1371/journal.pone.0082092. [PubMed: 24324749].
  • 13. Kalsch J, Bechmann LP, Kalsch H, Schlattjan M, Erhard J, Gerken G, et al. Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. J Nutr Metab. 2011;2011:369168. doi: 10.1155/2011/369168. [PubMed: 21773018].
  • 14. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27-33. doi: 10.1002/hep.21223. [PubMed: 16799979].
  • 15. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10(8):837-58. doi: 10.1016/j.cgh.2012.03.011. [PubMed: 22446927].
  • 16. Jian-gao F, Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010;18(3):163-6. [PubMed: 20698076].
  • 17. Rahman T, Islam S, Ferdoushi S, Mortaz RE, Bhuiyan MMA, Sultana T, et al. Association of serum cytokeratin-18 fragment concentration in patients with different types of nonalcoholic fatty liver disease. Gastroenterol Hepatol Open Access. 2015;2(2).
  • 18. Jomali R, Pourshams A, Amini S, Deyhim MR, Rezvan H, Malekzadeh R. The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med. 2008;11(6):602-7.
  • 19. Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepat Mon. 2013;13(12). e14679. doi: 10.5812/hepatmon.14679. [PubMed: 24358044].
  • 20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. doi: 10.1007/BF00280883. [PubMed: 3899825].
  • 21. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467-74. doi: 10.1111/j.1572-0241.1999.01377.x. [PubMed: 10484010].
  • 22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. doi: 10.1002/hep.20701. [PubMed: 15915461].
  • 23. Mohamed AK, Magdy M. Caspase 3 role and immunohistochemical expression in assessment of apoptosis as a feature of H1N1 vaccine-caused Drug-Induced Liver Injury (DILI). Electron Physician. 2017;9(5):4261-73. doi: 10.19082/4261. [PubMed: 28713494].
  • 24. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46(2):582-9. doi: 10.1002/hep.21768. [PubMed: 17661414].
  • 25. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci. 2005;10:3093-9. doi: 10.2741/1765. [PubMed: 15970563].
  • 26. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39(2):273-8. doi: 10.1002/hep.20051. [PubMed: 14767974].
  • 27. Gieseler RK, Marquitan G, Schlattjan M, Sowa JP, Bechmann LP, Timm J, et al. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepat. 2011;18(11):760-7. doi: 10.1111/j.1365-2893.2010.01362.x. [PubMed: 20723040].
  • 28. Takehara T, Tatsumi T, Suzuki T, Rucker EB 3rd, Hennighausen L, Jinushi M, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 2004;127(4):1189-97. doi: 10.1053/j.gastro.2004.07.019. [PubMed: 15480996].
  • 29. Chakraborty JB, Oakley F, Walsh MJ. Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol. 2012;2012:648915. doi: 10.1155/2012/648915. [PubMed: 22567408].
  • 30. Maher MM, Ibrahim WA, Saleh SA, Shash L, Abou Gabal H, Tarif M, et al. Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Egypt J Med Hum Genet. 2015;16(1):41-6. doi: 10.1016/j.ejmhg.2014.11.003.
  • 31. Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology. 2012;55(2):455-64. doi: 10.1002/hep.24734. [PubMed: 21993925].
  • 32. Hussien HM, Pasha HF, Mostafa NA. Apoptotic shards of cytokeratin 18 point to steatohepatitis in patients with nonalcoholic hepatic steatosis. Med J Cairo Univ. 2011;79(2):199-205.
  • 33. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26(2):151-6. doi: 10.1111/j.1478-3231.2005.01209.x. [PubMed: 16448452].
  • 34. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47(6):1916-23. doi: 10.1002/hep.22241. [PubMed: 18433022].
  • 35. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102(2):399-408. doi: 10.1111/j.1572-0241.2006.01041.x. [PubMed: 17311652].
  • 36. Francque SM, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10(10):1162-8. quiz e87. doi: 10.1016/j.cgh.2012.06.019. [PubMed: 22796457].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments